Industry News

Biocon Ltd on Friday said it plans to launch recombinant human- insulin and long-acting insulin glargine in Malaysia in the second half of this financial year, after it received regulatory approval from the South-East Asian nation. According to Biocon, the insulin market in Malaysia is pegged at around $40 million including sales from tenders and retail. The Malaysian approval comes months after Japanese approval for Biocon's insulin glargine, providing a..."/>
Biocon to launch two insulin variants in Malaysia in fiscal 2017 [Mint, New Delhi]
Centene Corp. has been selected to provide managed care support to the Department of Defense Tricare program across 21 western states starting in 2017.."/>
UnitedHealthcare losing big military health contract [Star Tribune (Minneapolis)]
Spectranetics Corp. won a year ago against the cofounder of a company the Colorado Springs-based medical device manufacturer bought in 2014, ruling a federal court in California lacked jurisdiction to hear the case. Court of Appeals for the Federal Circuit in Washington, D.C., reversed the damage award ruling by a federal district court in San Francisco that Eitan Konstantino, the former cofounder, officer..."/>
Colorado Springs-based Spectranetics loses judgment in federal court [The Gazette (Colorado Springs, Colo.)]
RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to proceed with a consolidation of its outstanding common shares on the basis of ten pre-consolidation Shares for one post-consolidation Share. Currently, a total of 67,261,629 Shares are issued and outstanding. Accordingly, if the..."/>
RepliCel Life Sciences Continues Restructuring With Share Structure Consolidation
Shire Plc, the company said. Chronos has acquired all intellectual property, know-how, development and marketing rights for each programme on a worldwide basis. Shire becomes a strategic equity investor in Chronos and is eligible for milestone payments on regulatory approval of products..."/>
UK Biotech Firm Chronos Therapeutics Acquires 3 Pre-Clinical Programmes from Shire
XBiotech Inc., developer of next-generation True Human™ antibody therapies, said today that the Independent Data Monitoring Committee for the XCITE Phase III clinical study of Xilonix™ for the treatment of colorectal cancer, recently recommended study continuation without any amendment to the study design. The DMC convened as scheduled, subsequent to the enrollment of 400 patients into the study.. The DMC mandate is to“ monitor for early evidence of..."/>
XBiotech Provides Update on Xilonix™ Phase III Programs in US and EU
Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has adjusted the subscription price and related pricing information for its previously announced rights offering. The subscription pricing is now $4.10 per unit. The subscription period for the rights offering commenced on July 8, 2016, and the subscription rights will..."/>
Onconova Adjusts Pricing of Rights Offering
Aequus Pharmaceuticals Inc. today announced Ann Fehr is joining the growing specialty pharmaceutical company as its new Chief Financial Officer effective July 22, 2016. Ms. Fehr brings to Aequus over 20 years of management experience in corporate finance, treasury, financial planning and analysis, tax, and risk management in a number of rapidly growing entrepreneurial companies. "We are very fortunate to have Ann join Aequus."/>
Aequus Appoints Ann Fehr as Chief Financial Officer
Aurinia Pharmaceuticals Inc. today announced that it has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald& Co. pursuant to which the Company may from time to time sell, through at-the-market offerings with Cantor acting as sales agent, such common shares as would have an aggregate offer price of up to US $10,000,000. Aurinia has also filed a prospectus supplement with securities regulatory authorities in Canada..."/>
Aurinia Establishes At-The-Market Facility
Teva Pharmaceutical Industries Ltd.. Teva previously issued $15 billion of USD-denominated bonds on July 18, 2016.. The approximately $20 billion of proceeds from the bond issuances, together with up to $5 billion of expected draws on committed term loan facilities, is expected to be used to fund the pending acquisition of the generic..."/>
Fitch Rates Teva Pharmaceutical's New EUR and CHF Bonds 'BBB'
Amgen today announced that it will report its second quarter financial results on Wednesday, July 27, 2016, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team."/>
Amgen Announces Webcast Of 2016 Second Quarter Financial Results
AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will present at the Canaccord Genuity Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 10, 2016. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’ s corporate website at"/>
AtriCure to Present at the Canaccord Genuity Growth Conference
Amgen today announced that its Board of Directors declared a $1.00 per share dividend for the third quarter of 2016. The dividend will be paid on Sept. 8, 2016, to all stockholders of record as of the close of business on Aug. 17, 2016.. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human..."/>
Amgen Announces 2016 Third Quarter Dividend
Sami Sagol: Portrait of Mr. Keter [Globes, Tel Aviv, Israel]
Teva Pharmaceutical Industries Ltd. announced last night that it had successfully priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands IV B.V. for 1 billion Swiss francs. The offering comprises three tranches: CHF300 million of 0.125% fixed rate senior notes maturing in 2018; CHF350 million of 0.500% fixed rate senior notes maturing in 2022; and CHF350 million of 1.000% fixed rate senior notes maturing in 2025.."/>
Teva raises 1b Swiss francs in debt [Globes, Tel Aviv, Israel]
Insmed Incorporated. Investors who purchased or otherwise acquired shares between March 18, 2013 and June 8, 2016, are encouraged to contact the firm in advance of the September 13, 2016 lead plaintiff motion deadline.. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Insmed Incorporated and Encourages Investors with Losses to Contact the Firm
Emergent BioSolutions, Inc.. Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 inclusive, are encouraged to contact the Firm prior to the September 19, 2016 lead plaintiff motion deadline.. If you purchased shares of Emergent during the Class Period, please contact Joon M. Khang, Esquire, of Khang& Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine,..."/>
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Reminds Investors with Losses to Contact the Firm
Synta Pharmaceuticals Corp., effective as of July 22, 2016.. The combined company has more than $40 million in cash to advance its research and development..."/>
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host a conference call and live audio webcast on Thursday, August 4, 2016, at 8:30 AM ET to report second quarter 2016 financial results and provide a corporate update. The live webcast can be accessed under "Events and Presentations" in the Investor..."/>
Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016
WellCare Names Ryan Randall COO, Georgia

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials843 Articles
Information Technology735 Articles
Consumer Discretionary685 Articles
Industrials531 Articles
Health Care466 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at